Affiliation:
1. National Medical Research Center for Hematology
2. N.N. Blokhin National Medical Research Center of Oncology
Abstract
The discovery of immune checkpoints (IC) has become a landmark event in immuno-oncolog y, improving the understanding of the mechanisms of tumor cells evading immune sur veillance. Based on this, a group of drugs such as immune checkpoint inhibitors (ICIs) were developed, the ef fect of which is due to the rupture of the immunological synapse and recognition by tumor T cells. Currently, ICIs are successfully used in the treatment of a number of malignant neoplasms, improving the indicators of diseasefree and overall sur vival. However, determining the role of these drugs in the treatment of children with tumors of the blood system is the subject of active research. This article presents a review of the literature on topical aspects of the administration of PD-1 and PD-L1 inhibitors in pediatric hematolog y. Their mechanisms of action, ef fectiveness and potential complications of therapy are presented.
Publisher
Paediatrician Publishers LLC